GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00144872
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 82
- Registration Number
- NCT00144859
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 740
- Registration Number
- NCT00144911
- Locations
- 🇨🇦
GSK Investigational Site, Sorel, Quebec, Canada
Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00144846
- Locations
- 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
- Conditions
- HIV-1
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00144833
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, London, United Kingdom
🇮🇹GSK Clinical Trials Call Centre, Torino, Italy
🇬🇧GSK Clinical Trials call Center, Birmingham, United Kingdom
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- Biological: GSK Biologicals' 719125
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3
- Registration Number
- NCT00140738
- Locations
- 🇵🇪
GSK Investigational Site, Lima, Peru
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00140712
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3994
- Registration Number
- NCT00140686
- Locations
- 🇪🇸
GSK Investigational Site, Sodupe (Vizcaya), Spain
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT00140725
- Locations
- 🇭🇰
GSK Investigational Site, Shatin, Hong Kong
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 63227
- Registration Number
- NCT00140673
- Locations
- 🇻🇪
GSK Investigational Site, Valencia, Carabobo, Venezuela